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Background:  Although  typhoid  fever  is  rare  in Japan, imported  cases  have been reported  occasionally
in  travelers  returning  from  endemic  areas.  To  achieve  licensing  of a typhoid  Vi  polysaccharide  vaccine
(Typhim  Vi®) and  make  it widely  available  in  Japan,  this  study  was  conducted  at the  request  of  the
Japanese  Ministry  of Health  Labor  and Welfare  to  assess  the  immunogenicity  and safety  of  this  vaccine
when  given  as a  single  dose  (the  recommended  schedule  of  administration)  in a Japanese  population.
Methods:  In this  multi-center,  open-label,  non-comparative,  intervention  study  performed  in  Japan,  200
healthy  volunteers  (188  adults  [≥18  years  of  age],  7  adolescents  [12–17  years  of age]  and  5 children  [2–11
years  of age])  were  administered  Typhim  Vi®. Immunogenicity  was assessed  28  days  after  vaccinations
using  an  ELISA  method  of anti-Vi  antibody  detection.  A 4-fold  increase  in anti-Vi  titer  was  considered
as  the  threshold  for seroconversion  for anti-Vi  antibodies.  Safety  was  assessed  up  to 28 days  following
vaccination.
Results:  Overall,  92.0%  (95%  conﬁdence  interval  [CI]: 87.3–95.4%)  of  participants  achieved  seroconversion
28  days  after  a  single  dose  of typhoid  Vi  polysaccharide  vaccine.  GMTs  of Vi  antibody  titers  increased  from
6.6 (95%  CI: 5.8–7.4)  prior  to vaccination  to 157.3 (95%  CI:  135.1–183.2)  on  Day  28 after  vaccination.  The
geometric  mean  of  individual  anti-Vi  antibody  titer ratios  (Day  28/Day  0) was  23.9  (95% CI: 20.3–28.3).
There  were  no  immediate  adverse  events  and  no  adverse  events  led  to the discontinuation  of  participants
from  the  study.  Across  all age  groups,  pain and  myalgia  were  the  most  frequently  reported  injection  site
and  systemic  reactions,  respectively.  Most  of these  reactions  were  mild  in intensity  and  resolved  within
7  days.
Conclusions:  A  single  dose  of  typhoid  Vi  polysaccharide  vaccine,  Typhim  Vi®, demonstrated  good  safety
and  immunogenicity  proﬁle  in  a Japanese  population.
ublis©  2015  The  Authors.  P
. IntroductionTyphoid fever remains a global public health concern and a
ajor cause of morbidity in developing countries in particular [1].
 Funded by Sanoﬁ Pasteur, ClinicalTrials.gov number: NCT01608815.
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It is a systemic illness caused by Salmonella enterica serotype Typhi
[1]. The disease is spread via the fecal–oral route as a result of
inadequate sanitation, poor personal and food-related hygiene [1].
Typhoid is rare in countries with high sanitation standards and
in most developed countries the disease occurs most often among
international travelers to and from endemic areas [2,3]. South Cen-
tral/Eastern Asia has the highest incidence of the disease (>100
per 100,000 cases annually), with the rest of Asia, Latin America,
the Caribbean and Oceania (excluding Australia and New Zealand)
considered to have a medium incidence of the disease (10–100 per
100,000 annually) [2]. Developed countries have much lower inci-
dences of typhoid fever (<10 per 100,000 annually) [2]. Crude and
adjusted global estimates for typhoid fever range from 11 to 21
million cases annually [4,5], with the number of related deaths
 under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
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stimated to be around 200,000 [4,6]. Typhoid fever in Japan is rare
ith <100 cases reported in a typical year [7]. However, >18 million
apanese travel overseas annually and the main destinations are in
sia (i.e. India, Indonesia and China) [8]. Most cases of typhoid fever
n Japan are imported cases in travelers returning from endemic
reas such as India, Indonesia, Nepal and the Philippines [7].
Currently typhoid fever can be effectively treated with antibiotic
rugs, but the increasing rates of antibiotic resistance suggest that
t is important to consider a more preventative medicine approach.
uch an approach might entail the targeted vaccination of high-risk
opulations, combined with the longer-term solutions of provision
f safe water and improved sanitation [9].
A number of typhoid Vi polysaccharide vaccines that provide
rotection against the disease are available and have been demon-
trated in clinical trials to have good safety and immunogenicity
roﬁles [10]. For travelers to South Asia and other endemic
ountries, the World Health Organization (WHO) and other
ational health bodies recommend vaccination against typhoid
11–13]. At present there are no typhoid vaccines licensed in Japan
nd as such the rate of vaccination among Japanese travelers is gen-
rally low [14]. As a result Japanese travelers may  be more at risk of
cquiring enteric fever while traveling through endemic countries
15]. This situation leads some physicians to personally import the
yphoid vaccine so that they can vaccinate individuals prior to their
ravels.
This clinical study was conducted to assess the immunogenic-
ty and safety of a single dose of a typhoid vaccine (Typhim Vi®),
o as to achieve registration of this vaccine in Japan and make it
idely available. Typhim Vi®, a typhoid Vi polysaccharide vaccine,
as selected because at the time the study was initiated, it was  the
nly typhoid vaccine with a single dose schedule (for subjects ≥2
ears of age) [12] and, it was and still is (as of September 2015), the
nly typhoid vaccine prequaliﬁed by WHO  [16,17]. WHO  prequaliﬁ-
ation of vaccines is a system that evaluates the safety, efﬁcacy and
anufacture of vaccines to ensure that vaccines meet the require-
ents for global supply through the United Nations [18].
. Methods
.1. Study design and participants
This was a multi-center, open-label, non-comparative, interven-
ion study performed at four centers in Japan between 26 May  and
8 Sep 2012 (https://www.clinicaltrials.gov/; [NCT01608815]). The
tudy was conducted in accordance with the ethical principles of
he Declaration of Helsinki and the International Conference on the
armonization-Good Clinical Practice. The study was  approved by
ach study site’s institutional review board, and all participants or
heir parents/guardians provided written informed consent/assent
efore entering the study.
Eligible participants were healthy volunteers aged 2 years or
lder. Female participants of childbearing potential, had to use an
ffective method of contraception starting at least 4 weeks before
accination until at least 4 weeks after vaccination.
Exclusion criteria: pregnancy (known pregnancy or a positive
erum and/or urine pregnancy test) or breast feeding; history of
yphoid fever or Salmonella typhi infection; previous vaccination
gainst S. typhi; known or suspected congenital or acquired immu-
odeﬁciency or receipt of immunosuppressive therapy; bleeding
isorder; systemic illness; receipt of any vaccine within the 4 weeks
efore the trial vaccination (except for inﬂuenza vaccination, which
ay  have been received at least 2 weeks before the study); receipt
f blood or blood-derived products in the past 3 months that might
ave interfered with assessment of the immune response or known
ystemic hypersensitivity to one of the vaccine component in the
ast.3 (2015) 6697–6702
2.2. Vaccine
The typhoid Vi polysaccharide vaccine Typhim Vi® was  pro-
vided in pre-ﬁlled syringes that contained 0.5 mL  of vaccine (Sanoﬁ
Pasteur Inc., France [Batch G0528-1]). Each dose of 0.5 mL  was
formulated to contain 25 g of puriﬁed Vi capsular polysaccha-
ride. The vaccine was administered intramuscularly into the deltoid
region at Day 0.
2.3. Immunogenicity assessments
Blood samples (5 mL)  were collected in dry sterile capped plastic
tubes for estimation of antibody titer against Vi antigen prior to
vaccination and 28 days post-vaccination. The blood was allowed
to clot before separation of serum by centrifuging at 3000 rpm for
10 min. The serum samples were stored at −20 ◦C or lower until
analysis.
Anti-Vi antibodies were measured by ELISA (VaccZymeTM
Human Anti-S typhi Vi IgG Enzyme Immunoassay Kit; The Binding
Site Group Ltd., Birmingham, UK) by Sanoﬁ Pasteur Central Labo-
ratories. Diluted serum samples (100 L) were added to wells of
antigen-coated microtitre test plates and incubated in the dark at
18–24 ◦C for 30 min. Each well was washed 3 times with 300 L of
wash buffer. 100 L puriﬁed peroxidase labeled rabbit anti-human
IgG ( chain speciﬁc) conjugate was  added to each well and the
plates incubated in the dark at 18–24 ◦C for 30 min. The wells
were washed an additional three times, tetramethylbenzidine sub-
strate added and incubated at room temperature in the dark for
30 min. The substrate reaction was then stopped with 100 L 3M
phosphoric acid and plates were read spectrophotometrically at
450 nm.  The assay was  calibrated against an afﬁnity puriﬁed prepa-
ration of pooled human antiserum to typhi Vi. The quantity of
IgG antibodies in the afﬁnity puriﬁed preparation was conﬁrmed
against the European Reference Material ERM®-DA470 (Institute
for Reference Materials and Measurements, Belgium). The anti-
typhi Vi units assigned to this assay were determined based upon
the quantity of IgG (EU/mL) in the binding site’s afﬁnity puriﬁed
reference material. The lower limit of quantiﬁcation for the assay
was 7.4 ELISA units/mL (EU/mL).
2.4. Safety
Participants were kept under observation for 30 min after the
vaccination to assess the occurrence of any immediate adverse
events/reactions. Participants or their parents/guardians were pro-
vided with diary cards, digital thermometers and ﬂexible rulers
to record solicited systemic and injection site reactions, as well
as other unsolicited adverse events/reactions. Solicited injection
site reactions (pain, erythema and swelling) and solicited systemic
reactions (fever, headache, malaise and myalgia) were recorded
daily for 7 days after vaccination along with any action taken to
manage each event. Body temperature was measured daily for 7
days after vaccination. Unsolicited adverse events were recorded
for 28 days after vaccination. Serious adverse events were recorded
throughout the study. Participants or their parents/guardians were
contacted by telephone 8 days (Day 8 ± 2 days) after vaccination
to remind them to record all safety information in the diary card.
Diary cards were collected from participants when they returned
for follow-up at visit 2 (Day 28 + 7 days).
Participants or their parents/guardians graded the intensity of
non-measurable solicited reactions and unsolicited adverse reac-
tions using a three-point grading scale of increasing severity: grade
1, no interference with activity; grade 2, some interference with
activity; and grade 3, signiﬁcant, prevents daily activity. Adverse
reactions of injection site erythema, swelling and pain were graded
on the three-point scale during statistical analysis according to age
M. Miyazu et al. / Vaccine 33 (2015) 6697–6702 6699
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fFig. 1. Geometric mean titers (GMTs) and 95% conﬁdence intervals (CIs) at ba
roup. For adults and adolescents ≥12 years of age, pain at the injec-
ion site was graded as: grade 1, no interference with activity; grade
, some interference with activity; and grade 3, signiﬁcant, prevents
aily activity. Injection site erythema and swelling were classiﬁed
s: grade 1: ≥2.5 to <5 cm;  grade 2: ≥5.1 to <10 cm;  and grade 3:
10 cm.  For children aged 2–11 years of age, pain at the injection
ite was graded as: grade 1, easily tolerated; grade 2, sufﬁciently
iscomforting to interfere with normal behavior or activities; Grade
, incapacitating, unable to perform usual activities. Injection site
rythema and swelling were classiﬁed as: grade 1: ≥0.0 to <2.5 cm;
rade 2: ≥2.5 to <5 cm;  and grade 3: ≥5 cm.  Fever was  also graded
n a 3-point scale deﬁned as body temperature ≥37.5◦ and clas-
iﬁed as grade 1, where the measured temperature ranged from
37.5 ◦C to ≤38.4 ◦C; grade 2: ≥38.5 ◦C to ≤38.9 ◦C; and grade 3:
39.0 ◦C, for all age groups.
Investigators assessed the causal relationship of each unso-
icited adverse event (serious or non-serious) as either not related
r related to vaccination. By convention, all solicited reactions (i.e.
hose pre-listed) and all injection site adverse reactions (irrespec-
ive of whether they are pre-listed or not) that occurred within 7
ays after vaccination were considered to be related to vaccination.
.5. Statistical analyses
There were no statistically powered pre-deﬁned hypotheses in
his study. The number of participants required was set to provide
upportive immunogenicity and safety data for the typhoid Vi
olysaccharide vaccine when administered as a single dose. The
re-set level of seroconversion rate was set at 75%. Assuming an
xpected seroconversion rate of 85%, a sample size of 180 evalu-
ble participants would ensure a 95% CI above the pre-set level
ith a power of 90%. This sample size allowed, with 95% probabil-
ty, to detect an adverse event occurring with a frequency of 1.6%
r more. To allow for a 10% drop-out rate, 200 participants were
nrolled.
All participants who received the study vaccine were included
n the immunogenicity and safety analysis. As there is currently no
alidated correlate of seroprotection for Vi antibody titers, a 4-fold
ncrease in post-vaccination antibody titer from pre-vaccination
evels was considered as the threshold for seroconversion [19–21].
eometric mean of the titers (GMTs) and the GMT  ratios (Day
8/Day 0) with corresponding 95% conﬁdence intervals (CIs) were
alculated by taking the antilog of the mean of the log2 trans-
ormed data (assuming that log2 transformation of the titers follows and 28 days following injection with the typhoid Vi polysaccharide vaccine.
a normal distribution). The incidences of adverse events were also
calculated.
3. Results
3.1. Study population
A total of 200 participants were enrolled in this study: 188
adults (≥18 years), 7 adolescents (12–17 years) and 5 children
(2–11 years). All participants complied with all the inclusion crite-
ria and none had any exclusion criteria. All participants completed
the study. There was  only one protocol deviation in this study; one
participant provided a serology sample on Day 27 instead of Day
28 as planned.
Both the immunology analysis set and the safety analysis set
included 200 participants. The baseline characteristics of the study
participants are summarized in Table 1. All participants were of
Asian/oriental ethnic origin of whom 62% were male. The age of
participants ranged from 2 years to 57 years (median 36 years).
3.2. Immunogenicity
Overall, 92% of participants achieved seroconversion 28 days
after a single vaccination with typhoid Vi polysaccharide vaccine
(i.e. with a ≥4-fold rise in Vi antibody titers between Day 0 before
vaccination and Day 28 after vaccination). The proportion of par-
ticipants, in each age group, who  seroconverted is summarized in
Table 2. GMTs of Vi antibody titers increased from 6.6 (95% CI:
5.8–7.4) prior to vaccination to 157.3 (95% CI: 135.1–183.2) on
Day 28 after vaccination (Fig. 1). The geometric mean of individ-
ual titer ratio (Day 28/Day0) was  23.9 (95% CI: 20.3–28.3). The
reverse cumulative distribution curve for Vi antibody titers in the
immunology analysis set is illustrated in Fig. 2.
3.3. Safety
There were no immediate adverse events. There were no
adverse events that led to discontinuation of participants in the
study, nor any deaths reported during the study. One participant
experienced a serious adverse event during the study. The seri-
ous adverse event (hepatobiliary disorders/acute cholecystitis) was
reported in an adult participant 7 days after administration of study
vaccine and was assessed by the investigator as unrelated to vacci-
nation (the patient had a history of gallstones).
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Table 1
Baseline characteristics of participants.
Adults
[≥18 years]
(N = 188)
Adolescents
[12–17 years]
(N = 7)
Children
[2–11 years]
(N = 5)
All
(N = 200)
Sex
Males, n (%) 116 (61.7) 4 (57.1) 4 (80.0) 124 (62.0)
Female, n (%) 72 (38.3) 3 (42.9) 1 (20.0) 76 (38.0)
Age  (years)
Mean age ± SD 37.2 ± 11.4 15.6 ± 2.0 5.2 ± 3.8 35.7 ± 12.7
Median (min–max) 38.0 (19–57) 17.0 (12–17) 3.0 (2–11) 36.0 (2–57)
Weight (kg)
Mean weight ± SD 61.1 ± 11.9 58.8 ± 11.6 18.6 ± 9.4 59.9 ± 13.5
Median (min–max) 59.5 (38.2–119.7) 58.1 (44.8–77.5) 14.0 (12.7–35.0) 59.1 (12.7–119.7)
Race
Asian/oriental, n (%) 188 (100) 7 (100) 5 (100) 200 (100)
Min, minimum; max, maximum; SD, standard deviation.
Table 2
Immunogenicity (primary endpoint).
Adults (≥18 years)
N = 188
Adolescents (12–17 years)
N = 7
Children (2–11 years)
N = 5
All
N = 200
Vi antibody
≥4-fold rise, n (%) 173 (92%) 6 (85.7%) 5 (100%) 184 (92.0%)
[95%  CI]a [87.2–95.5%] [42.1–99.6%] [47.8–100%] [87.3–95.4%]
Pre-vaccination GMT  (Day 0) 6.6 10.2 3.7 6.6
[95%  CI]a [5.8–7.4] [2.9–35.9] NC [5.8–7.4]
Post-vaccination GMT  (Day 28) 148.6 320.0 501.7 157.3
[95%  CI]a [126.9–174.0] [230.6–444.2] [305.3–824.5] [135.1–183.2]
Day 28/Day 0 GMT ratio 22.6 31.4 135.6 23.9
[95%  CI]a [19.1–26.8] [9.2–107.9] [82.5–222.8] [20.3–28.3]
C
g
w
a
tI, conﬁdence interval; GMT, geometric mean titer; NC, not calculated.
a Estimated by Clopper-Pearson exact method.
The incidence of solicited reactions by age group, after a sin-
le dose of typhoid Vi polysaccharide is detailed in Table 3. Pain
as the most frequent solicited injection site reaction across all
ge groups. Overall, 74.0% (n = 148) of participants reported injec-
ion site pain, and 0.5% (n = 1) reported injection site swelling.
Fig. 2. Reverse cumulative distribution curve for Vi aInjection site erythema was  reported by two participants (1%). Most
injection site reactions were of grade 1 intensity and none were of
grade 3 intensity. All injection site reactions occurred between Day
0 and Day 3 and the majority of these reactions resolved within
3 days.
ntibody titers in the Immunology analysis set.
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Table  3
Frequency of solicited injection site and systemic reactions during the 7 days after vaccination by age group.
Symptom Severity Adults [≥18
years] (N = 188)
Adolescents
[12–17 years] (N = 7)
Children
[2–11 years]
(N = 5)
All
(N = 200)
n  (%) n (%) n (%) n (%)
Injection site reaction Any 139 (73.9) 6 (85.7) 3 (60.0) 148 (74.0)
Pain Any  139 (73.9) 6 (85.7) 3 (60.0) 148 (74.0)
Grade 3 0 0 0 0
Erythema Any  0 0 2 (40.0) 2 (1.0)
Grade  3 0 0 0 0
Swelling Any  1 (0.5) 0 0 1 (0.5)
Grade  3 0 0 0 0
Systemic reaction Any 104 (55.3) 4 (57.1) 2 (40.0) 110 (55.0)
Fever Any  2 (1.1) 0 1 (20.0) 3 (1.5)
Grade  3 0 0 0 0
Headache Any  14 (7.4) 0 0 14 (7.0)
Grade 3 1 (0.5) 0 0 1 (0.5)
Malaise Any  23 (12.2) 0 0 23 (11.5)
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TGrade 3 2 (1.1)
Myalgia Any  93 (49.5) 
Grade 3 2 (1.1) 
Myalgia was the most frequently reported solicited systemic
eaction in all age groups. In adults, 49.5% (n = 93) of the participants
eported myalgia, 12.2% (n = 23) malaise, 7.4% (n = 14) headache
nd 1.1% (n = 2) fever. Systemic reactions were mostly of grade
 or grade 2 intensity. In 4 adults a total of 5 events, including
eadache, malaise or myalgia, were reported to be of grade 3 inten-
ity (note, one participant reported two grade 3 events). In most
dults, systemic reactions occurred between Day 0 and Day 3 and
esolved within 7 days. In adolescents, myalgia was reported in
 participants (57.1%, 4/7 participants) and were all of grade 1
ntensity. All cases of myalgia occurred between Day 0 and Day
 and resolved within 3 days. No fever, headache and malaise
ere reported in adolescents. In children, a systemic reaction was
eported in 2 participants (40.0%, 2/5 participants). Fever and myal-
ia were reported in one child participant each; both were of grade
 intensity. Fever occurred between Day 4 and Day 7 and resolved
ithin 7 days following health care provider contact and prescrip-
ion of a new medication. Myalgia occurred between Day 0 and Day
 and resolved within 3 days.
No unsolicited systemic adverse reactions were reported across
ll age groups. Two adults experienced an unsolicited injection
ite reaction (injection site hemorrhage and pruritus, respectively);
hese were automatically assessed as related to the vaccination
ue to the localization at injection site. In adults, 10.6% (n = 20) of
he participants reported a total of 23 unsolicited systemic adverse
vents. In adults, the most frequently reported unsolicited adverse
vents were nasopharyngitis (3.7%, n = 3) followed by dysmenor-
hea (2.1%, n = 4) and headache (1.1%, n = 2). The majority of the
nsolicited systemic adverse events were of grade 1 or grade 2
ntensity. One grade 3 event (gastroenteritis) was  reported in one
articipant; prescription of a new medication was required. In ado-
escents, an unsolicited systemic adverse event was reported in
ne participant (grade 1, stomatitis). In children, an unsolicited
ystemic adverse event was reported in one participant (grade 1,
asopharyngitis).
. Discussion
This study showed that the typhoid Vi polysaccharide vaccine
yphim Vi® has a good immunogenicity and safety proﬁle in a
apanese population. The vaccine administered as a single dose was
ighly immunogenic with a high proportion (>90%) of participants
chieving a ≥4-fold rise in Vi antibody titers across all age groups.
here were no immediate adverse events and no adverse events 0 2 (1.0)
 (57.1) 1 (20.0) 98 (49.0)
 0 2 (1.0)
that led to discontinuation of participants in the study. Across all
age groups, pain and myalgia were the most frequently reported
injection site and systemic reactions, respectively, however most
of these were of mild intensity and resolved within 7 days.
Overall, the seroconversion rate (≥4-fold rise in Vi antibody
titers between Day 0 before vaccination and Day 28 after vacci-
nation) achieved with the typhoid Vi polysaccharide vaccine in
the current Japanese study (92%) appears comparable with that
reported in other non-endemic regions. A US study, conducted in
182 healthy adults aged 18–40 years of age vaccinated against
typhoid, reported a seroconversion rate of 93% [22]. In a study
conducted in Nepal that recruited students from France and the
USA, as well as Nepalese inhabitants, following vaccination against
typhoid, seroconversion rates were higher for French and US stu-
dents (96%) compared with participants living in Nepal (75%), an
endemic country [23]. The seroconversion rate in Nepalese chil-
dren was comparable to that in Nepalese adults <45 years of age,
whereas seroconversion rates in Nepalese adults aged 45–55 years
of age appeared to be lower (50–63%); however, more participants
in each age group would be required to conﬁrm this. In all these
studies, seroconversion was deﬁned as a ≥4-fold rise in Vi antibody
titers between Day 0 before vaccination and Day 28 after vacci-
nation, however, the methods used to measure Vi antibody titers
varied between studies.
With the exception of reported rates of injection site pain,
the rate of adverse events reported in this study is consistent
with or lower than the published literature. Reports of erythema
were higher in a study using a Vi polysaccharide vaccine (5%) [22]
compared with the present study (1%), and in a meta-analysis of
typhoid vaccine studies, the rate of injection site swelling was also
higher (2.9%) [10] compared with the present study (0.5%). How-
ever, injection site pain, while transient and mild, was  reported by
almost three-quarters of study participants, which was consider-
ably higher than the 0.5% reported in a study in China reported by
Yang et al. [24]. However, efﬁcacy was the primary objective of the
study reported by Yang et al. whereas adverse event data was only
collected passively (i.e. reports from parents), which may explain
the difference in the ﬁndings between the two  studies [24].
5. LimitationsThere are limitations of our study that should be considered.
Firstly, the age range of participants was relatively narrow: very
few children and adolescents were recruited (only ﬁve children
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nd seven adolescents) and the study population did not include
lderly participants (the eldest participant was 57 years old). Sec-
ndly, the sex-ratio was unbalanced with a larger number of men
han women included (62% versus 38%). In addition, as recruit-
ent in this study was primarily intended for participants needing
yphoid vaccination i.e. traveling to epidemic or endemic areas,
ecruitment was anticipated to be relatively slow and thus a con-
rol group was not included. Inclusion of a comparator vaccine or
lacebo control group would have enhanced the interpretation of
he immunogenicity and safety data, in this study. Of note, this
tudy was conducted in Japan at the request of the Japanese Min-
stry of Health Labor and Welfare. As such, extrapolation of these
nding to other geographical areas may  not be appropriate given
hat differences in sanitation and epidemiology between countries
ay  occur.
Seroconversion rates were reported in the current study rather
han seroprotection rates because there is currently no established
ut-off level of Vi antibodies that correlates with protection from
linical disease [19]. The seroconversion rate threshold selected in
his study (≥4-fold rise in Vi antibody titers) is consistent with that
sed in other studies and WHO  guidelines for typhoid conjugate
accines [19–21,23,25,26]; however, a 4-fold rise in Vi antibody
iters can only be used as an indicator of the immune response
nd does not guarantee protection against typhoid. Furthermore,
he current study assessed relatively short term immunogenicity
nd therefore cannot inform us as to long-term immunogenicity. A
hree-year study in 37 adults in a region non-endemic for typhoid
ound that anti-Vi antibody concentrations declined progressively
uring the study [27].
In conclusion, the typhoid Vi polysaccharide vaccine Typhim Vi®
as sufﬁciently immunogenic and well tolerated without safety
oncerns.
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